Encorafenib market outlook remains robust as targeted therapies for BRAF‑mutated melanoma and colorectal cancer expand. The market’s attractiveness is driven by high unmet clinical need, premium pricing, and favorable reimbursement pathways in North America and Europe, delivering an estimated CAGR above 12% through 2032. Competitive intensity is moderate; while vemurafenib and dabrafenib dominate the BRAF‑inhibitor space, few direct entrants challenge encorafenib’s differentiated efficacy and safety profile, though biosimilar pressure may rise post‑patent expiry. Long‑term outlook is positive, supported by pipeline extensions into adjuvant settings and combination regimens with MEK inhibitors and immunotherapies, which broaden the addressable patient pool. Innovation is vigorous, with ongoing trials exploring novel dosing schedules and biomarker‑guided selection, reinforcing the product’s clinical relevance. Demand‑supply balance is currently stable, with manufacturers scaling capacity to meet projected volume growth; however, supply chain disruptions in API sourcing could strain availability. Key risks include regulatory delays for new indications, aggressive pricing reforms, and potential safety signals emerging from real‑world evidence.
